Poly Medicure reports strong Q2 FY26 results, strategic acquisitions underway

Poly Medicure Limited reported consolidated revenue growth of 5.7% for Q2 FY26, reaching INR 443.9 Crs, with H1 FY26 revenue at INR 847.1 Crs, up 5.3% year-over-year. Operating EBITDA grew by 2.5% in Q2 FY26 to INR 118.8 Crs, and 2.6% in H1 FY26 to INR 225.9 Crs. PAT for Q2 FY26 was INR 91.8 Crs, a 5.0% increase, and INR 184.9 Crs for H1 FY26, up 14.5%. The company maintains a healthy liquidity position with net cash of INR 1,109.1 Crs as of September 30, 2025.

Strategic initiatives include the completed acquisitions of PendraCare Group (Netherlands) for Cardiology and Citieffe Group (Italy) for Orthopaedics, expanding Poly Medicure’s global footprint and product portfolio. The PendraCare acquisition, closed on September 22, 2025, generated €9.9 million in CY24 revenue, while the Citieffe acquisition, closed on November 6, 2025, contributed €17.3 million in CY24 revenue. The company also launched 8 new products in Q2 FY26 and established the "Polymed Academy of Clinical Excellence" (PACE) for professional training.

Domestic revenue for Q2 FY26 increased by 16.9% to INR 140.9 Crs, and international revenue grew by 1.4% to INR 300.3 Crs. Infusion Therapy remains the largest segment, contributing INR 273.5 Crs, though it saw a slight decrease of 2.4% in Q2 FY26 compared to the previous year. Renal and Others segments grew by 18.1% and 23.0% respectively in Q2 FY26.